雲頂新耀-B(01952.HK)治療轉移性尿路上皮癌全球3期臨床試驗在中國完成首例患者給藥
雲頂新耀-B(01952.HK)公布,戈沙妥珠單抗(sacituzumab govitecan-hziy)治療轉移性尿路上皮癌全球3期臨床試驗TROPiCS-04在中國完成首例患者給藥。
集團指,TROPiCS-04是一項全球多中心、開放標籤、隨機臨床試驗,旨在經鉑化療和PD-1/PD-L1抗體治療後仍發生疾病進展的轉移性或者局部晚期不可切除的尿路上皮癌患者中,評估比較戈沙妥珠單抗和醫生選擇治療(TPC)。這項臨床試驗的主要終點是總生存期。(ek/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.